SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI), which will become effective prior to the open of U.S. markets on Monday, December 18, 2017.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharmaceutical, according to the Industry Classification Benchmark. Additional information about the index is available here.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high-grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG and the European Medicines Agency (EMA) has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of HGG.
View original content with multimedia:http://www.prnewswire.com/news-releases/tocagen-added-to-nasdaq-biotechnology-index-300571308.html
SOURCE Tocagen Inc.
Monica May, Canale Communications, (619) 849-5383, firstname.lastname@example.org, Elizabeth Broder, The Trout Group, (646) 378-2945, email@example.com